GeneGene: GLP1R

GLP-1 receptor (GLP1R)

The glucagon-like peptide-1 receptor (GLP-1R) regulates insulin secretion, appetite, and gastric emptying. Agonists — increasingly oral, nonpeptide small molecules — drive substantial weight loss and glycemic control and now anchor the obesity and type-2 diabetes markets.

Forecast a trial in the ArenaAll targets & genes
2
Drugs
2
Trials tracked
0
Resolved
1
Indications

Drugs hitting this target

Orforglipron· Oral nonpeptide GLP-1 receptor agonistAleniglipron· Oral small-molecule GLP-1 receptor agonist

Trials targeting GLP-1R

2 benchmarks
OpenPhase 3

ATTAIN-MAINTAIN (orforglipron) weight maintenance after switching from Wegovy or Zepbound

Orforglipron · Obesity

Dec 18, 2025Clinical Trials
OpenPhase 2b

ACCESS (aleniglipron) Phase 2b obesity

Aleniglipron · Obesity

Dec 8, 2025Clinical Trials

Indications

Obesity

About GLP-1R

What is GLP-1R?

The glucagon-like peptide-1 receptor (GLP-1R) regulates insulin secretion, appetite, and gastric emptying. Agonists — increasingly oral, nonpeptide small molecules — drive substantial weight loss and glycemic control and now anchor the obesity and type-2 diabetes markets.

Which drugs target GLP-1R?

Therapies acting on GLP-1R tracked here include Orforglipron, Aleniglipron.

References

Keep exploring

All benchmarksDiseasesDrugsCompanies